Modified Zhujing formula combined with ranibizumab for wet age-related macular degeneration
10.3980/j.issn.1672-5123.2026.7.06
- VernacularTitle:驻景方加减联合雷珠单抗治疗湿性年龄相关性黄斑变性
- Author:
Rui GAO
1
;
Pineng HU
1
;
Meijiao ZHOU
1
;
Jian ZHANG
1
;
Yu ZHANG
1
;
Tiejun ZHANG
1
;
Wujun LI
1
Author Information
1. Department of Ophthalmology,Yulin Hospital of Traditional Chinese Medicine, Yulin 719200, Shaanxi Province, China
- Publication Type:Journal Article
- Keywords:
Zhujing formula;
ranibizumab;
wet age-related macular degeneration;
clinical efficacy
- From:
International Eye Science
2026;26(7):1141-1146
- CountryChina
- Language:Chinese
-
Abstract:
AIM:To analyze the efficacy of modified Zhujing formula combined with intravitreal ranibizumab(IVR)injection in the treatment of wet age-related macular degeneration(wARMD).METHODS: A prospective study was conducted on wARMD patients at the Ophthalmology Department of Yulin Hospital of Traditional Chinese Medicine from September 2022 to October 2024. The study subjects were divided into the experimental group and the control group according to the random number table method. The control group received IVR treatment, while the experimental group was treated with modified Zhujing formula in addition to IVR injection. The clinical efficacy, TCM symptom scores, central retinal thickness(CRT), best corrected visual acuity(BCVA), macular hemorrhage area, choroidal neovascularization area(CNV), ocular hemodynamic parameters [resistance index(RI), maximum diastolic blood flow(EDV), maximum systolic blood flow(PSV)], and 1-year recurrence rate were compared between the two groups.RESULTS: This study included 60 eyes from 60 wARMD patients. Among them, the control group consisted of 30 patients and 30 eyes, while the experimental group consisted of 30 patients and 30 eyes. The age of the control group was 67.52±3.12 y, with 17 males and 13 females. The age of the experimental group was 67.62±3.04 y, with 18 males and 12 females.The clinical efficacy of the experimental group(97%)was higher than that of the control group(73%)(P<0.05). After treatment, the scores of blurred vision, soreness and weakness of the waist and knees, restlessness and insomnia, dizziness and tinnitus in the experimental group were all lower than those in the control group(all P<0.05); the EDV and PSV in the experimental group were both higher than those in the control group(both P<0.05); the BCVA, CRT, macular hemorrhage area, CNV and RI of the experimental group were all lower than those of the control group(all P<0.05), and the 1-year recurrence rate in the experimental group(3%)was lower than that in the control group(27%)(P<0.05). CONCLUSION:The combined use of modified Zhujing formula and IVR can effectively alleviate symptoms such as blurred vision and retinal hemorrhage in wARMD patients, improve vision and ocular hemodynamic conditions, and reduce the recurrence rate. This suggests that there may be a synergistic enhancing effect.
